神経障害薬の世界市場2019-2027:産業分析、規模、シェア、成長、動向、予測

• 英文タイトル:Neurological Disorder Drugs Market (Disorder: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others; Drug Class: Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedatives, Analgesics, Antihypertensive, Anticoagulants, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027

Neurological Disorder Drugs Market (Disorder: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others; Drug Class: Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedatives, Analgesics, Antihypertensive, Anticoagulants, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027「神経障害薬の世界市場2019-2027:産業分析、規模、シェア、成長、動向、予測」(市場規模、市場予測)調査レポートです。• レポートコード:D0JU09097
• 出版社/出版日:Transparency Market Research / 2020年3月11日
• レポート形態:英文、PDF、251ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥620,065 (USD5,795)▷ お問い合わせ
  Multi User¥941,065 (USD8,795)▷ お問い合わせ
  Corporate License¥1,262,065 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、神経障害薬の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、障害別(てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他)分析、薬物クラス別(抗コリン作用薬、抗てんかん薬、抗精神病薬、催眠薬、鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他分析、流通経路別(小売薬局、病院薬局、オンライン薬局)分析、地域別分析、競争状況などの構成でお届けいたします。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場動向
・市場概要
・キーインサイト
・神経障害薬の世界市場:障害別(てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳血管疾患、その他)
・神経障害薬の世界市場:薬物クラス別(抗コリン作用薬、抗てんかん薬、抗精神病薬、催眠薬、鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他
・神経障害薬の世界市場:流通経路別(小売薬局、病院薬局、オンライン薬局)
・神経障害薬の世界市場:地域別
・競争状況

Neurological Disorder Drugs Market – Scope of the Report

TMR’s report on the global neurological disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the global neurological disorder drugs market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neurological disorder drugs market from 2019 to 2027.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global neurological disorder drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neurological disorder drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global neurological disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neurological disorder drugs market.

The report also delves into the competitive landscape of the global neurological disorder drugs market. Key players operating in the global neurological disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neurological disorder drugs market that have been profiled in this report.

Key Questions Answered in Neurological Disorder Drugs Market Report

What is the sales/revenue generated by neurological disorder drugs across all regions during the forecast period?
What are the opportunities in the global neurological disorder drugs market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which disorder segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Neurological Disorder Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global neurological disorder drugs market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global neurological disorder drugs market in terms of disorder, drug class, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neurological disorder drugs market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurological Disorder Drugs Market

4. Market Overview

4.1. Introduction & Overview

4.2. Product Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Neurological Disorder Drugs Market Analysis and Forecast, 2017–2027

5. Market Outlook

5.1. Pipeline Analysis

5.2. Disease Prevalence & Incidence Rate globally with key countries

5.3. Regulatory Scenario

6. Global Neurological Disorder Drugs Market Analysis and Forecast, by Disorder

6.1. Introduction & Definition

6.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

6.2.1. Epilepsy

6.2.2. Alzheimer Disease

6.2.3. Multiple Sclerosis

6.2.4. Parkinson Disease

6.2.5. Cerebrovascular Diseases

6.2.6. Others

6.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder

7. Global Neurological Disorder Drugs Market Analysis and Forecast, by Drug Class

7.1. Introduction & Definition

7.2. Global Neurological Disorder Drugs Market Value (US$) Forecast, by Drug Class, 2017–2027

7.2.1. Anticholinergic

7.2.2. Antiepileptic

7.2.3. Antipsychotic

7.2.4. Analgesic

7.2.5. Hypnotic & Sedative

7.2.6. Antihypertensive

7.2.7. Anticoagulants

7.2.8. Others

7.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class

8. Global Neurological Disorder Drugs Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition

8.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

8.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Neurological Disorder Drugs Market Analysis and Forecast, by Region

9.1. Key Findings

9.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region

10. North America Neurological Disorder Drugs Market Analysis and Forecast

10.1. Introduction

10.2. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

10.2.1. Epilepsy

10.2.2. Alzheimer Disease

10.2.3. Multiple Sclerosis

10.2.4. Parkinson Disease

10.2.5. Cerebrovascular Diseases

10.2.6. Others

10.3. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

10.3.1. Anticholinergic

10.3.2. Antiepileptic

10.3.3. Antipsychotic

10.3.4. Analgesic

10.3.5. Hypnotic & Sedative

10.3.6. Antihypertensive

10.3.7. Anticoagulants

10.3.8. Others

10.4. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. North America Neurological Disorder Drugs Market Attractiveness Analysis

10.6.1. By Disorder

10.6.2. By Drug Class

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Neurological Disorder Drugs Market Analysis and Forecast

11.1. Introduction

11.2. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

11.2.1. Epilepsy

11.2.2. Alzheimer Disease

11.2.3. Multiple Sclerosis

11.2.4. Parkinson Disease

11.2.5. Cerebrovascular Diseases

11.2.6. Others

11.3. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

11.3.1. Anticholinergic

11.3.2. Antiepileptic

11.3.3. Antipsychotic

11.3.4. Analgesic

11.3.5. Hypnotic & Sedative

11.3.6. Antihypertensive

11.3.7. Anticoagulants

11.3.8. Others

11.4. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Neurological Disorder Drugs Market Attractiveness Analysis

11.6.1. By Disorder

11.6.2. By Drug Class

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

12.2.1. Epilepsy

12.2.2. Alzheimer Disease

12.2.3. Multiple Sclerosis

12.2.4. Parkinson Disease

12.2.5. Cerebrovascular Diseases

12.2.6. Others

12.3. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

12.3.1. Anticholinergic

12.3.2. Antiepileptic

12.3.3. Antipsychotic

12.3.4. Analgesic

12.3.5. Hypnotic & Sedative

12.3.6. Antihypertensive

12.3.7. Anticoagulants

12.3.8. Others

12.4. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.5.1. China

12.5.2. Japan

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis

12.6.1. By Disorder

12.6.2. By Drug Class

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Neurological Disorder Drugs Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

13.2.1. Epilepsy

13.2.2. Alzheimer Disease

13.2.3. Multiple Sclerosis

13.2.4. Parkinson Disease

13.2.5. Cerebrovascular Diseases

13.2.6. Others

13.3. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

13.3.1. Anticholinergic

13.3.2. Antiepileptic

13.3.3. Antipsychotic

13.3.4. Analgesic

13.3.5. Hypnotic & Sedative

13.3.6. Antihypertensive

13.3.7. Anticoagulants

13.3.8. Others

13.4. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Neurological Disorder Drugs Market Attractiveness Analysis

13.6.1. By Disorder

13.6.2. By Drug Class

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Neurological Disorder Drugs Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

14.2.1. Epilepsy

14.2.2. Alzheimer Disease

14.2.3. Multiple Sclerosis

14.2.4. Parkinson Disease

14.2.5. Cerebrovascular Diseases

14.2.6. Others

14.3. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

14.3.1. Anticholinergic

14.3.2. Antiepileptic

14.3.3. Antipsychotic

14.3.4. Analgesic

14.3.5. Hypnotic & Sedative

14.3.6. Antihypertensive

14.3.7. Anticoagulants

14.3.8. Others

14.4. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis

14.6.1. By Disorder

14.6.2. By Drug Class

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Competition Matrix

15.2. Market Share Analysis, by Company, 2018

15.3. Company Profiles

15.3.1. Novartis AG

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Company Financials

15.3.1.3. Growth Strategies

15.3.1.4. SWOT Analysis

15.3.2. GlaxoSmithKline plc

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Company Financials

15.3.2.3. Growth Strategies

15.3.2.4. SWOT Analysis

15.3.3. F. Hoffmann-La Roche Ltd.

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Company Financials

15.3.3.3. Growth Strategies

15.3.3.4. SWOT Analysis

15.3.4. Pfizer, Inc.

15.3.4.1. Company Overview (HQ, Business Segments)

15.3.4.2. Company Financials

15.3.4.3. Growth Strategies

15.3.4.4. SWOT Analysis

15.3.5. Bayer AG

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Company Financials

15.3.5.3. Growth Strategies

15.3.5.4. SWOT Analysis

15.3.6. Boehringer Ingelheim International GmbH

15.3.6.1. Company Overview (HQ, Business Segments)

15.3.6.2. Company Financials

15.3.6.3. Growth Strategies

15.3.6.4. SWOT Analysis

15.3.7. AstraZeneca plc

15.3.7.1. Company Overview (HQ, Business Segments)

15.3.7.2. Company Financials

15.3.7.3. Growth Strategies

15.3.7.4. SWOT Analysis

15.3.8. Teva Pharmaceutical Industries Ltd.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Company Financials

15.3.8.3. Growth Strategies

15.3.8.4. SWOT Analysis

15.3.9. Merck & Co., Inc.

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Company Financials

15.3.9.3. Growth Strategies

15.3.9.4. SWOT Analysis

15.3.10. Otsuka Pharmaceutical Co., Ltd.

15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.10.2. Company Financials

15.3.10.3. Growth Strategies

15.3.10.4. SWOT Analysis

15.3.11. Amgen, Inc.

15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.11.2. Company Financials

15.3.11.3. Growth Strategies

15.3.11.4. SWOT Analysis

15.3.12. UCB S.A.

15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.12.2. Company Financials

15.3.12.3. Growth Strategies

15.3.12.4. SWOT Analysis

15.3.13. Eli Lilly and Company

15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.13.2. Company Financials

15.3.13.3. Growth Strategies

15.3.13.4. SWOT Analysis

15.3.14. Biogen

15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.14.2. Company Financials

15.3.14.3. Growth Strategies

15.3.14.4. SWOT Analysis

List of Tables

Table 01: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 03: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 06: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 10: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 12: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 13: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 14: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 18: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 20: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 21: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017–2027

Table 22: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027


• 英文レポート名:Neurological Disorder Drugs Market (Disorder: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others; Drug Class: Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedatives, Analgesics, Antihypertensive, Anticoagulants, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027
• 日本語訳:神経障害薬の世界市場2019-2027:産業分析、規模、シェア、成長、動向、予測
• レポートコード:D0JU09097お問い合わせ(見積依頼・ご注文・質問)